Valchlor
PreclinicalSmall molecule
Valchlor is one of 20 small molecule programs targeting Cutaneous T-cell lymphoma. It is currently in Preclinical.
1
Indications
2
Total Trials
0
Active Trials
19
Competitors
Pipeline
Status by Indication[3][1]
Indication
Competition
Competitive Landscape
19 competitors in Cutaneous T-Cell Lymphoma
#DrugCompanyPhaseTrials
1Adcetris
PfizerApproved
Trexall
Jazz PharmaceuticalsApproved
Targretin
BBausch Health Americas, Inc.
Approved
Venclexta
AbbVieApproved
Tecfidera
BiogenApproved
Adriamycin
PfizerApproved
Revlimid
KKaruna Therapeutics, Inc., a Bristol Myers Squibb company
Approved
Vibramycin
PPfizer's Upjohn has merged with Mylan to form Viatris Inc.
Approved
Beleodaq
AAcrotech Biopharma Inc.
Approved
Aldara
BBausch Health Americas, Inc.
Approved
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Clinical
Trials by Indication[1]
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for Valchlor. EMBL-EBI & Wellcome Sanger Institute.
- [4]
Details
Drug Info
Quick Facts
- Modality
- Small molecule[2]
- Highest Phase
- Preclinical[1]
- Company
- HHelsinn Therapeutics (U.S.), Inc